TIDMBVX

RNS Number : 8726K

BiVictriX Therapeutics PLC

31 August 2023

BiVictriX Therapeutics plc

("BiVictriX" or the "Company")

Total Voting Rights

Alderley Park, UK, 31 August 2023: BiVictriX Therapeutics plc, an emerging biotechnology company applying a differentiated approach to develop next-generation cancer therapies with substantially improved cancer cell selectivity and anti-cancer activity, announces, for the purposes of the FCA's Disclosure and Transparency Rules, that the total issued share capital of the Company consists of 82,526,088 ordinary shares of 1 pence each with voting rights.

The total number of voting rights in the Company is 82,526,088 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in the interest in, the share capital of the Company.

ENDS

 
 For more information, please contact: 
   BiVictriX Therapeutics plc 
   Tiffany Thorn, Chief Executive Officer 
    Michael Kauffman, Non-Executive Chairman     Email: info@bivictrix.com 
 
   SP Angel Corporate Finance LLP (NOMAD        Tel: +44 (0) 20 3470 
    and Broker)                                  0470 
   David Hignell, Kasia Brzozowska (Corporate 
    Finance) 
    Vadim Alexandre, Rob Rees (Sales and 
    Broking) 
 
    Panmure Gordon (UK) Limited (Joint           Tel: +44 (0) 20 7886 
    Broker)                                      2500 
   Rupert Dearden/Freddy Crossley/Emma 
    Earl 
 
    Consilium Strategic Communications 
   Mary-Jane Elliott, Namrata Taak,             Tel: +44 (0) 20 3709 5700 
    Max Bennett, Emmalee Hoppe                   Email: Bivictrix@consilium-comms.com

About BiVictriX Therapeutics plc

BiVictriX (AIM: BVX) is an emerging biotechnology company leveraging clinical experience and its proprietary discovery engine to advance a new class of highly cancer-selective, next-generation precision cancer therapies in one of the fastest-growing markets in oncology. BiVictriX's first-in-class Bi-Cygni(R) Antibody Drug Conjugates ("ADCs") combine superior efficacy with substantially improved cancer-selectivity and safety to provide opportunities for prolonged dosing and greater efficacy in the clinic. The Company is advancing its pipeline to deliver the future of cancer care across a broad range of haematological and solid cancer indications in areas of high unmet medical need.

Find out more at www.bivictrix.com and connect with us on LinkedIn and Twitter @BiVictriX .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVREAEPEDLEDEAA

(END) Dow Jones Newswires

August 31, 2023 02:00 ET (06:00 GMT)

Bivictrix Therapeutics (LSE:BVX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Bivictrix Therapeutics Charts.
Bivictrix Therapeutics (LSE:BVX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Bivictrix Therapeutics Charts.